News & Events
< Back to News Overview
C-Pulse abstract presented at ISHLT Meeting, Boston
08 / 04 / 2008
Sunshine Heart, Inc. (ASX:SHC) announced today that a presentation at 28th Annual Meeting of the International Society for Heart and Lung Transplantation (ISHLT) will highlight results from the first human trial of the Company's C-PulseT System, an implantable, non-blood contacting heart assist therapy for the treatment of moderate heart failure. The ISHLT meeting will take place April 9-12 at the Hynes Convention Center in Boston, MA.
Sunshine Heart's oral abstract presentation, entitled, "First-in-Human Study of a Novel Implantable Extra-Ascending Aortic Counterpulsation Pump in Patients with End-Stage Heart Failure," covers the Australian / New Zealand clinical study in Class III-IV end stage heart failure patients aged 54-73 who underwent C-Pulse implantation. Results which have also been presented at the Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand, showed that C-Pulse provided long-term relief of heart failure symptoms and substantially improved cardiac performance. The abstract summarizes C-Pulse results from Auckland City Hospital, St Vincents Hospital, Sydney, Royal Perth Hospital, Perth and Southern Health Monash Medical Centre, Melbourne. The abstract will be presented by Associate Professor Christopher Hayward, Cardiologist at the Heart Failure and Transplant Unit at St Vincent''s Hospital, Sydney. Mr Hayward also has a Conjoint Appointment at the University of NSW.
In preparation for the pending US feasibility clinical trial, Sunshine Heart will hold a US Investigator's meeting prior to the ISHLT meeting. Clinical research personnel from the six premier US medical institutions participating in the trial are scheduled to attend, including the institutions' investigational cardiac surgeons and cardiologists.
Donald Rohrbaugh, Chief Executive Officer, said, "We are extremely pleased to be presenting data from our C-Pulse ANZ pilot study for the first time in the US at the ISHLT meeting. This annual meeting is an excellent forum for bringing together medical professionals from around the world involved in the management and treatment of heart and lung disease. We believe that C-Pulse offers unique advantages to both patients and clinicians and is a truly innovative heart assist device, with the potential to significantly improve patient quality of life. C-Pulse is inserted in a straightforward manner, it pumps blood without contacting blood and can be turned on and off safely. The data from the ANZ pilot study highlights these key features. Sunshine Heart is working actively with the FDA to attain approval to initiate our US feasibility trial in the second half of 2008."
Sunshine Heart's oral abstract presentation, entitled, "First-in-Human Study of a Novel Implantable Extra-Ascending Aortic Counterpulsation Pump in Patients with End-Stage Heart Failure," covers the Australian / New Zealand clinical study in Class III-IV end stage heart failure patients aged 54-73 who underwent C-Pulse implantation. Results which have also been presented at the Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand, showed that C-Pulse provided long-term relief of heart failure symptoms and substantially improved cardiac performance. The abstract summarizes C-Pulse results from Auckland City Hospital, St Vincents Hospital, Sydney, Royal Perth Hospital, Perth and Southern Health Monash Medical Centre, Melbourne. The abstract will be presented by Associate Professor Christopher Hayward, Cardiologist at the Heart Failure and Transplant Unit at St Vincent''s Hospital, Sydney. Mr Hayward also has a Conjoint Appointment at the University of NSW.
In preparation for the pending US feasibility clinical trial, Sunshine Heart will hold a US Investigator's meeting prior to the ISHLT meeting. Clinical research personnel from the six premier US medical institutions participating in the trial are scheduled to attend, including the institutions' investigational cardiac surgeons and cardiologists.
Donald Rohrbaugh, Chief Executive Officer, said, "We are extremely pleased to be presenting data from our C-Pulse ANZ pilot study for the first time in the US at the ISHLT meeting. This annual meeting is an excellent forum for bringing together medical professionals from around the world involved in the management and treatment of heart and lung disease. We believe that C-Pulse offers unique advantages to both patients and clinicians and is a truly innovative heart assist device, with the potential to significantly improve patient quality of life. C-Pulse is inserted in a straightforward manner, it pumps blood without contacting blood and can be turned on and off safely. The data from the ANZ pilot study highlights these key features. Sunshine Heart is working actively with the FDA to attain approval to initiate our US feasibility trial in the second half of 2008."